Selectivity is key when meeting gold standards of future prostate cancer care. Diaprost´s monoclonal antibody platform will provide the best option for diagnosing and treating prostate cancer.
ANTIBODY PLATFORM FOR SPECIFIC DETECTION AND TREATMENT
Prostate Specific Antigen (PSA) and human Kallikrein 2 (hK2) are antigens known to be abundant in prostate tissue. However, it is a well established fact in vitro tests for PSA levels are effective but not efficient. Instead hK2 for in vivo screening will increase both effectiveness and efficiency.
The Diaprost pipeline covers humanized antibodies for both diagnostics and therapeutics targeting the hK2 antigen as well as therapy targeting the PSA antigen.
The h11B6 enables therapy of prostatic cancer through radioimmunotherapy and detection of prostate metastases by PET in combination with anatomical imaging (CT/MR), as well as intra-operative imaging.
The h5A10 will provide therapy of prostatic cancer through radioimmunotherapy targeting PSA expressing prostatic tissue.